Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
作者信息
Tam Constantine S, Kamel Sarah
机构信息
Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia
Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
出版信息
Haematologica. 2016 Mar;101(3):e123. doi: 10.3324/haematol.2015.139030.
Abstract
摘要
相似文献
1
Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.对利普斯基等人的评论：接受依鲁替尼治疗的慢性淋巴细胞白血病患者出血相关不良事件的发生率及危险因素
Haematologica. 2016 Mar;101(3):e123. doi: 10.3324/haematol.2015.139030.
2
Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.对关于接受依鲁替尼治疗的慢性淋巴细胞白血病患者出血相关不良事件的发生率和危险因素的评论的回应。
Haematologica. 2016 Mar;101(3):e124-5. doi: 10.3324/haematol.2015.140558.
3
Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
Br J Haematol. 2016 Apr;173(2):327-8. doi: 10.1111/bjh.13601. Epub 2015 Jul 20.
4
Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?伊布替尼用于慢性淋巴细胞白血病：单独使用还是联合使用？
Lancet Oncol. 2016 Feb;17(2):129-131. doi: 10.1016/S1470-2045(15)00519-7. Epub 2015 Dec 5.
5
Bleeding complications in chronic lymphocytic leukaemia.
Acta Univ Palacki Olomuc Fac Med. 1990;125:121-6.
6
Massive oral bleeding after full-mouth extraction in a patient with B-cell lymphocytic leukemia/small lymphocytic lymphoma reversed with recombinant activated factor VII.一名B细胞淋巴细胞白血病/小淋巴细胞淋巴瘤患者在全口拔牙后出现大量口腔出血，使用重组活化因子VII后出血得到逆转。
J Am Dent Assoc. 2016 Feb;147(2):142-5. doi: 10.1016/j.adaj.2015.09.001. Epub 2015 Nov 6.
7
8
The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.伊布替尼在慢性淋巴细胞白血病治疗中的新作用。
Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.
9
Response to Comment by Amato T. .对阿马托·T.评论的回应
Haematologica. 2019 Nov;104(11):e541. doi: 10.3324/haematol.2019.224303.
10
Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. 2015;126(19):2213-2219.勘误：孙C、田X、李YS等。依鲁替尼治疗慢性淋巴细胞白血病患者的体液免疫部分重建及感染减少。2015年；126(19):2213 - 2219。
Blood. 2016 Aug 18;128(7):1020. doi: 10.1182/blood-2016-06-725010.
引用本文的文献
1
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.依鲁替尼对慢性淋巴细胞白血病患者通过光透射聚集法评估的瑞斯托霉素诱导的血小板聚集没有影响。
Haematologica. 2018 Mar;103(3):e119-e122. doi: 10.3324/haematol.2017.179044. Epub 2017 Dec 14.
本文引用的文献
1
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.接受依鲁替尼治疗的慢性淋巴细胞白血病患者出血相关不良事件的发生率及危险因素
Haematologica. 2015 Dec;100(12):1571-8. doi: 10.3324/haematol.2015.126672. Epub 2015 Oct 1.
2
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.伊布替尼治疗影响胶原和血管性血友病因子依赖的血小板功能。
Blood. 2014 Dec 18;124(26):3991-5. doi: 10.1182/blood-2014-06-583294. Epub 2014 Oct 10.
3
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.伊布替尼抑制胶原介导的血小板聚集，但不抑制 ADP 介导的血小板聚集。
Leukemia. 2015 Apr;29(4):783-7. doi: 10.1038/leu.2014.247. Epub 2014 Aug 20.
4
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
5
Ibrutinib in relapsed chronic lymphocytic leukemia.依鲁替尼用于复发的慢性淋巴细胞白血病
N Engl J Med. 2013 Sep 26;369(13):1277-8. doi: 10.1056/NEJMc1309710.
6
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.伊布替尼治疗复发慢性淋巴细胞白血病的 BTK 靶点。
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
Zotero 插件